FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to chemical-pharmaceutical industry, medicine and pharmacology, particularly to invention refers to, and can be used in development of antimycotic preparations of amphotericin B exhibiting low nephro- and hepatotoxicity. For the purpose of providing higher therapeutic efficacy, lower toxicity of a pharmaceutical composition, improved stability of amphotericin B as an ingredient, it contains oxidised dextrane produced by dextrane oxidation by potassium permanganate in an acid medium. It also contains a liposome-forming agent representing phosphatidylcholine. The ingredients of the pharmaceutical composition are related as follows: amphotericin B: oxidised dextrane: a liposome-forming agent: a pharmaceutically acceptable solvent as 0.0005:1-10:0.1-1.0:solvent up to 100 wt % respectively.
EFFECT: composition shows high efficacy.
2 cl, 3 ex
Title | Year | Author | Number |
---|---|---|---|
PHARMACEUTICAL TUBERCULOSIS COMPOSITION | 2008 |
|
RU2372914C1 |
MEDICATION FOR PREVENTION OF BIRD FLU IN MAMMALS | 2010 |
|
RU2437664C1 |
METHOD OF PRODUCING OXIDISED DEXTRAN, SUITABLE FOR ITS VISUALIZATION IN BLOOD SERUM | 2019 |
|
RU2690380C1 |
PHARMACEUTICAL COMPOSITION FOR TREATING TICK-BORNE ENCEPHALITIS | 2012 |
|
RU2472504C1 |
PHARMACEUTICAL COMPOSITION FOR TREATING BURNS | 2012 |
|
RU2473349C1 |
WOUND-HEALING MEANS | 2017 |
|
RU2644255C1 |
PHARMACEUTICAL COMPOSITION FOR TREATING CYTOSTATIC MYELOSUPPRESSION | 2012 |
|
RU2471490C1 |
METHOD FOR REDUCING TOXICITY OF AMPHOTERICIN B | 2005 |
|
RU2297246C1 |
DRUG STIMULATING PRODUCTION OF GRANULOCYTE-MACROPHAGE COLONY-FORMING FACTOR IN CELLS OF MONONUCLEAR PHAGOCYTE SYSTEM | 2010 |
|
RU2438676C1 |
MEANS FOR PREVENTION OF INTERSTITIAL PNEUMONIA | 2020 |
|
RU2747550C1 |
Authors
Dates
2011-10-10—Published
2010-07-12—Filed